Basimglurant not checked
Noema Pharma AG · NOE-101
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability. Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo. OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1.”In the company’s words, NCT05217628 on ClinicalTrials.gov
- Tested for
- Trigeminal Neuralgia
- Main trialPhase 2/3
- “Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice. This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.”In the company’s words, NCT05217628 on ClinicalTrials.gov
- Other names
- NOE-101
Other drugs for Trigeminal Neuralgia
- RP-008Kriya Therapeutics, Inc. · Phase 1/2
Coming up1
- 2 Feb 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | 2 Feb 2027 | An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | |
| Phase 2Completed | 6 Feb 2025 | Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026